1. Home
  2. CDNA vs NMFC Comparison

CDNA vs NMFC Comparison

Compare CDNA & NMFC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CDNA
  • NMFC
  • Stock Information
  • Founded
  • CDNA 1998
  • NMFC 2010
  • Country
  • CDNA United States
  • NMFC United States
  • Employees
  • CDNA N/A
  • NMFC N/A
  • Industry
  • CDNA Medical Specialities
  • NMFC Finance/Investors Services
  • Sector
  • CDNA Health Care
  • NMFC Finance
  • Exchange
  • CDNA Nasdaq
  • NMFC Nasdaq
  • Market Cap
  • CDNA 1.0B
  • NMFC 1.2B
  • IPO Year
  • CDNA 2014
  • NMFC 2011
  • Fundamental
  • Price
  • CDNA $19.21
  • NMFC $10.66
  • Analyst Decision
  • CDNA Buy
  • NMFC Hold
  • Analyst Count
  • CDNA 6
  • NMFC 3
  • Target Price
  • CDNA $30.33
  • NMFC $11.00
  • AVG Volume (30 Days)
  • CDNA 989.3K
  • NMFC 464.7K
  • Earning Date
  • CDNA 07-30-2025
  • NMFC 07-30-2025
  • Dividend Yield
  • CDNA N/A
  • NMFC 12.37%
  • EPS Growth
  • CDNA N/A
  • NMFC N/A
  • EPS
  • CDNA 1.07
  • NMFC 0.99
  • Revenue
  • CDNA $346,421,000.00
  • NMFC $366,773,000.00
  • Revenue This Year
  • CDNA $13.31
  • NMFC N/A
  • Revenue Next Year
  • CDNA $15.46
  • NMFC N/A
  • P/E Ratio
  • CDNA $17.90
  • NMFC $10.70
  • Revenue Growth
  • CDNA 25.92
  • NMFC N/A
  • 52 Week Low
  • CDNA $14.09
  • NMFC $8.84
  • 52 Week High
  • CDNA $34.84
  • NMFC $12.55
  • Technical
  • Relative Strength Index (RSI)
  • CDNA 57.48
  • NMFC 51.11
  • Support Level
  • CDNA $18.64
  • NMFC $10.21
  • Resistance Level
  • CDNA $19.44
  • NMFC $10.43
  • Average True Range (ATR)
  • CDNA 0.75
  • NMFC 0.18
  • MACD
  • CDNA -0.05
  • NMFC -0.02
  • Stochastic Oscillator
  • CDNA 46.86
  • NMFC 43.82

About CDNA CareDx Inc.

CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically the company generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.

About NMFC New Mountain Finance Corporation

New Mountain Finance Corp is a closed-end, non-diversified management investment company. It invests in equity interests such as preferred stock, common stock, warrants, or options received in connection with debt investments or may include direct investment in the equity of private companies. The company's investment objective is to generate current income and capital appreciation through sourcing and origination of debt securities at all levels of the capital structure, including first and second-lien debt, notes, bonds and mezzanine securities.

Share on Social Networks: